

## **Supporting Information**


# **Total Synthesis of Talarolide A and *atrop*-Talarolide A: Hydroxamate H-Bond Bridge Stabilization of Cyclic Peptide Conformers Invokes Non-Canonical Atropisomerism.**

Waleed M. Hussein\*, Yuxuan Zhu, Angela A. Salim and Robert J. Capon\*


Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, 4072, Australia

\* Correspondence: RJC: r.capon@uq.edu.au; WMH: w.hussein@uq.edu.au.


## 1. Spectroscopic characterisation of *atrop*-talarolide A (8)




**Figure S1.** MSMS chromatograms of *atrop*-talarolide A (8) (top) and natural talarolide A (1) (bottom)




**Figure S2.** UPLC-DAD (210 nm) chromatograms of (A) natural talarolide A (1), (B) *atrop*-talarolide A (8), and (C) co-injection of 1 and 8.




**Figure S3.** Overlay of  $^1\text{H}$  NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectra of *atrop*-talarolide A (**8**) (red) and natural talarolide A (**1**) (blue).



**Figure S4.** Overlay of HSQC (600 MHz,  $\text{DMSO}-d_6$ ) spectra of *atrop*-talarolide A (**8**) (red) and natural talarolide A (**1**) (blue) - annotated, \* indicates signals from the major conformer of *atrop*-talarolide A (**8**).



**Figure S5.** ROESY NMR (600 MHz, DMSO-*d*<sub>6</sub>) spectrum of *atrop*-talarolide A (**8**). There were no observable ROESY correlations from *N*-OH-Gly. Black box highlighted ROESY correlations between *N*Me-Tyr<sup>7</sup>-7OH and *N*Me-Tyr<sup>7</sup>-6/8. \*NH are not assigned to a particular amino acid residue.



**Figure S6.** ROESY NMR (600 MHz, DMSO-*d*<sub>6</sub>) spectrum of natural talarolide A (**1**). Red box highlighted ROESY correlations between *N*-OH-Gly to protons of other amino acid residues in close proximity. Black box highlighted ROESY correlations between *N*Me-Tyr<sup>7</sup>-7OH and *N*Me-Tyr<sup>7</sup>-6/8.

# Mass Spectrum Molecular Formula Report

## Analysis Info



Analysis Name	D:\Data\salim\Tal_A_synt.d	Acquisition Date	5/24/2023 12:15:24 PM
Method	tune-med_AP.m	Operator	a.salim
Sample Name		Instrument / Ser#	micrOTOF
Comment			213750.00 232

## Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.8 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	5.0 l/min
Scan End	1000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source


## Generate Molecular Formula Parameter

Formula, min.		
Formula, max.		
Measured m/z	Tolerance	Charge
Check Valence	Minimum	Maximum
Nirogen Rule	Electron Configuration	
Filter H/C Ratio	Minimum	Maximum
Estimate Carbon		



Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdb	e <sup>-</sup> Conf	N-Rule
740.3984	1	C <sub>35</sub> H <sub>55</sub> N <sub>7</sub> NaO <sub>9</sub>	740.3953	4.2	26.4	1	100.00	11.5	even	ok

**Figure S7.** HRMS measurement for *atrop*-talarolide A (**8**) obtained from Scheme 2.





**Figure S8.** UPLC-DAD (210 nm) chromatograms of *atrop*-talarolide A (**8**) obtained from (A) Scheme 2 and (B) Scheme 3 and (C) co-injection of both.

## Mass Spectrum Molecular Formula Report

Analysis Info		Acquisition Date	10/21/2023 12:50:20 PM
Analysis Name	D:\Data\salim\Tal_A_synt_2.d		
Method	tune-med_AP.m	Operator	a.salim
Sample Name		Instrument / Ser#	micrOTOF 213750.00
Comment			232

Acquisition Parameter					
Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.8 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	5.0 l/min
Scan End	1000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source


Generate Molecular Formula Parameter		
Formula, min.		
Formula, max.		
Measured m/z	Tolerance	Charge
Check Valence	Minimum	Maximum
Nirogen Rule	Electron Configuration	
Filter H/C Ratio	Minimum	Maximum
Estimate Carbon		




Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdb	e <sup>-</sup> Conf	N-Rule
740.3975	1	C35H55N7NaO9	740.3953	-2.9	27.4	1	100.00	11.5	even	ok

**Figure S9.** HRMS measurement for *atrop*-talarolide A (**8**) obtained from Scheme 3


## 2. Spectroscopic characterisation of synthetic talarolide A (1)




**Figure S10.** Overlay of  $^1\text{H}$  NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectra of synthetic (red) and natural (blue) talarolide A.



**Figure S11.** Expanded HSQC (600 MHz, DMSO-*d*<sub>6</sub>) spectra of synthetic (top) and natural (bottom) talarolide A showing the alpha protons region.



**Figure S12.** MSMS chromatograms of synthetic (top) and natural (bottom) talarolide A (**1**)



**Figure S13.** UPLC-DAD (210 nm) chromatograms of (A) natural and (B) synthetic talarolide A.

## Mass Spectrum Molecular Formula Report



Analysis Info		Acquisition Date	10/21/2023 12:45:34 PM
Analysis Name	D:\Data\salim\Synthetic talarolide A.d		
Method	tune-med_AP.m	Operator	a.salim
Sample Name		Instrument / Ser#	micrOTOF
Comment			213750.00 232

### Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.8 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	5.0 l/min
Scan End	1000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source

### Generate Molecular Formula Parameter


Formula, min.		
Formula, max.		
Measured m/z	Tolerance	
Check Valence	Minimum	Charge
Nitrogen Rule	Electron Configuration	Maximum
Filter H/C Ratio	Minimum	Maximum
Estimate Carbon		




Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdb	e <sup>-</sup> Conf	N-Rule
740.3973	1	C <sub>35</sub> H <sub>55</sub> N <sub>7</sub> NaO <sub>9</sub>	740.3953	-2.6	14.3	1	100.00	11.5	even	ok

**Figure S14.** HRMS measurement for synthetic talarolide A (**1**)


### 3. Characterisation of synthetic intermediates





**Figure S15.** HPLC-DAD-MS chromatograms of protected linear peptide **5**. (A) DAD chromatogram at 210 nm, (B) MS(+) total ion chromatogram, (C) MS spectrum at 5.14 min.




**Figure S16.** HPLC-DAD-MS chromatograms of protected cyclic peptide **6**. (A) DAD chromatogram at 210 nm, (B) MS(+) extracted ion chromatogram at 864, (C) MS spectrum at 3.13 min.



**Figure S17.** HPLC-DAD-MS chromatograms of crude semi-protected cyclic peptide 7 without *tert* butyl group. (A) DAD chromatogram at 210 nm, (B) MS(+) total ion chromatogram, (C) MS(+) extracted ion chromatogram at 808, (D) MS spectrum at 5.8 min.



**Figure S18.** HPLC-DAD-MS chromatograms of crude semi-protected linear peptide **9** without *tert* butyl group. (A) DAD chromatogram at 210 nm, (B) MS(+) total ion chromatogram, (C) MS(+) extracted ion chromatogram at 826, (D) MS spectrum at 4.5 min.



**Figure S19.** HPLC-DAD-MS chromatograms of unprotected linear peptide **10**. (A) DAD chromatogram at 210 nm, (B) MS(+) total ion chromatogram, (C) MS(+) extracted ion chromatogram at 736, (D) MS spectrum at 4.1 min.